Serum High-sensitivity C-reactive Protein As a Biomarker in Patients with Metabolic Syndrome: Evidence-based Study with 7284 Subjects

Overview

Journal Eur J Clin Nutr

Specialty Nutritional Sciences

Date 2016 Jul 28

PMID 27460263

Citations 30

Authors

S R Mirhafez

M Ebrahimi

M Saberi Karimian

A Avan

M Tayefi

A Heidari-Bakavoli

M R Parizadeh

M Moohebati

M R Azarpazhooh

H Esmaily

M Nematy

M Safarian

G A Ferns

M Ghayour-Mobarhan

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Metabolic syndrome (MetS) is characterized by abdominal obesity, dyslipidemia, hypertension and glucose intolerance, and is associated with an increased risk of developing cardiovascular disease (CVD), diabetes mellitus and related diseases. Circulating levels of inflammatory markers such as C-reactive-protein (CRP) have reported to be associated with CVD. Against this background, the prevalence of MetS is increasing globally, and thus predictive biomarkers are required for identification of MetS patients at an increased risk. Here we explored the value of CRP as a biomarker in 7284 subjects and also investigated which features of MetS have the greatest association with the hs-CRP level.

Subjects/methods: The subjects were recruited from the Mashhad stroke and heart atherosclerotic disorder study. Anthropometric factors and biochemical parameters (for example, high-sensitivity CRP (hs-CRP), high-density lipoprotein/low-density lipoprotein, triglycerides (TGs) and fasting blood glucose (FBG)) were determined. Univariate and multivariate analyses were conducted to evaluate the association of hs-CRP and MetS.

Results: Our results illustrated that the concentration of serum hs-CRP increased progressively with the number of MetS components, and subjects who fulfilled the criteria of MetS for waist circumference, TGs, blood pressure and FBG were found to have hs-CRP of 0.53, 0.38, 0.34 and 0.71 mg/l, respectively, higher than matched-subjects. Importantly, FBG had the greatest association with hs-CRP concentration.

Conclusions: Our data demonstrate the significant association between MetS components with hs-CRP, indicating that this association was cumulative by increasing the number of the defining features of MetS, supporting further studies to explore the value of emerging marker as a novel method for detecting individuals at high risk of developing MetS.

Citing Articles

Association Between High-Sensitivity C-Reactive Protein Trajectories and the Incidence of Metabolic Syndrome:A Retrospective Cohort Study.

Pan J, Cai X, Chen J, Xu M, Hu J, Mao Y J Inflamm Res. 2024; 17:8501-8511.

PMID: 39534057 PMC: 11556323. DOI: 10.2147/JIR.S493111.

Analysis of C-reactive protein omics-measures associates methylation risk score with sleep health and related health outcomes.

Wang Z, Wallace D, Spitzer B, Huang T, Taylor K, Rotter J medRxiv. 2024; .

PMID: 39281736 PMC: 11398435. DOI: 10.1101/2024.09.04.24313008.

C-reactive protein (CRP) evaluation in human urine using optical sensor supported by machine learning.

Cierpiak K, Wityk P, Kosowska M, Sokolowski P, Talaska T, Gierowski J Sci Rep. 2024; 14(1):18854.

PMID: 39143107 PMC: 11324656. DOI: 10.1038/s41598-024-67821-0.

Insulin resistance-related circulating predictive markers in the metabolic syndrome: a systematic review in the Iranian population.

Zahedi A, Zarkesh M, Sedaghati-Khayat B, Hedayati M, Azizi F, Daneshpour M J Diabetes Metab Disord. 2024; 23(1):199-213.

PMID: 38932859 PMC: 11196549. DOI: 10.1007/s40200-023-01347-6.

Association of maternal exposure to endocrine disruptor chemicals with cardio-metabolic risk factors in children during childhood: a systematic review and meta-analysis of cohort studies.

Rahimlou M, Mousavi M, Chiti H, Peyda M, Mousavi S Diabetol Metab Syndr. 2024; 16(1):82.

PMID: 38576015 PMC: 10993545. DOI: 10.1186/s13098-024-01320-0.

References

Kurtz E, Ridker P, Rose L, Cook N, Everett B, Buring J . Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes. Menopause. 2010; 18(1):23-9. PMC: 2974756. DOI: 10.1097/gme.0b013e3181e750dd. View

Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M . Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349(9050):462-6. DOI: 10.1016/s0140-6736(96)07591-5. View

Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T . Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2(7):800-3. DOI: 10.1038/nm0796-800. View

Manjunath D, Uthappa C, Kattula S, Allam R, Chava N, Oruganti G . Metabolic syndrome among urban Indian young adults: prevalence and associated risk factors. Metab Syndr Relat Disord. 2014; 12(7):381-9. DOI: 10.1089/met.2014.0003. View

Chen H, Cowan M, Hasday J, Vogel S, Medvedev A . Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol. 2007; 179(9):6097-106. DOI: 10.4049/jimmunol.179.9.6097. View

Beltran-Sanchez H, Harhay M, Harhay M, McElligott S . Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013; 62(8):697-703. PMC: 3756561. DOI: 10.1016/j.jacc.2013.05.064. View

Shea J, King M, Yi Y, Gulliver W, Sun G . Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutr Metab Cardiovasc Dis. 2011; 22(9):741-7. DOI: 10.1016/j.numecd.2010.11.009. View

Guerrero-Romero F, Rodriguez-Moran M . Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003; 29(1):65-71. DOI: 10.1016/s1262-3636(07)70009-5. View

Zuliani G, Volpato S, Galvani M, Ble A, Bandinelli S, Corsi A . Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis. 2008; 203(2):626-32. PMC: 2710530. DOI: 10.1016/j.atherosclerosis.2008.07.038. View

10.

Frohlich M, Imhof A, Berg G, Hutchinson W, Pepys M, Boeing H . Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000; 23(12):1835-9. DOI: 10.2337/diacare.23.12.1835. View

11.

Sesmilo G, Biller B, Llevadot J, Hayden D, Hanson G, Rifai N . Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000; 133(2):111-22. DOI: 10.7326/0003-4819-133-2-200007180-00010. View

12.

Kang E, Kim H, Ahn C, Park C, Cha B, Lim S . Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005; 69(2):151-9. DOI: 10.1016/j.diabres.2004.11.014. View

13.

Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G . Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004; 292(12):1440-6. DOI: 10.1001/jama.292.12.1440. View

14.

Perez Fernandez R, Kaski J . [Interleukin-10 and coronary disease]. Rev Esp Cardiol. 2002; 55(7):738-50. DOI: 10.1016/s0300-8932(02)76693-1. View

15.

de Ferranti S, Gauvreau K, Ludwig D, Newburger J, Rifai N . Inflammation and changes in metabolic syndrome abnormalities in US adolescents: findings from the 1988-1994 and 1999-2000 National Health and Nutrition Examination Surveys. Clin Chem. 2006; 52(7):1325-30. DOI: 10.1373/clinchem.2006.067181. View

16.

Mirhafez S, Pasdar A, Avan A, Esmaily H, Moezzi A, Mohebati M . Cytokine and growth factor profiling in patients with the metabolic syndrome. Br J Nutr. 2015; 113(12):1911-9. DOI: 10.1017/S0007114515001038. View

17.

Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K . Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004; 43(6):1318-23. DOI: 10.1161/01.HYP.0000129281.03801.4b. View

18.

Shifren J, Rifai N, Desindes S, McIlwain M, Doros G, Mazer N . A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab. 2008; 93(5):1702-10. DOI: 10.1210/jc.2007-2193. View

19.

Soto Gonzalez A, Bellido Guerrero D, Buno Soto M, Pertega Diaz S, Martinez-Olmos M, Vidal O . Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr. 2006; 60(6):802-9. DOI: 10.1038/sj.ejcn.1602384. View

20.

Wang L, Zheng B, Zhao H, Du P, Sun A, Hua K . α-Adducin gene G614T polymorphisms in essential hypertension patients with high low density lipoprotein (LDL) levels. Indian J Med Res. 2014; 139(2):273-8. PMC: 4001340. View